meRfi®-GM

Vancomycin & Clostridioides difficile infection (CDI) (recurrent)

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Vancomycin remains the 1st-line treatment for multiply recurrent C difficile infection
Ma et al. 2017 Ann Intern Med 167: 152–58

…

Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection
Hvas et al. 2019 Gastroenterology 156: 1324–32
Fidaxomicin versus vancomycin for Clostridium difﬁcile infection
Louie et al. 2011 N Engl J Med 364: 422-431
Fidaxomicin versus vancomycin for infection with Clostridium difﬁcile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Cornely et al. 2012 Lancet Infect Dis 12: 281-289
Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: a cohort study
Ma et al. 2017 Ann Intern Med 167: 152–58
Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection
Cammarota et al. 2015 Aliment Pharmacol Ther 41: 835–43
Treatment of ﬁrst recurrence of Clostridium difﬁcile infection: ﬁdaxomicin versus vancomycin
Cornely et al. 2012 Clin Infect Dis 55: S154-S161